Bioinformatic analysis reveals prognostic value and immunotherapy potential of Siglec-15 in laryngeal squamous cell carcinoma [PDF]
HeliyonBackground: Laryngeal squamous cell carcinoma (LSCC) is the ultimate common malignant head and neck cancer with dismal prognosis. The expression pattern and clinical significance of Siglec-15 (Sialic acid-binding immunoglobulin-like lectin 15) in LSCC ...
Xiaoting Chen +4 more
doaj +4 more sources
Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer [PDF]
BMC CancerThe sialic acid binding Ig like lectin 15 (Siglec-15) was previously identified as tumor immune suppressor gene in some human cancers with elusive molecular mechanism to be elucidated.
Xingzhi Li +6 more
doaj +4 more sources
Siglec-15 as a potential molecule involved in osteoclast differentiation and bone metabolism [PDF]
HeliyonSialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is a well-conserved type I transmembrane protein of the Siglecs family, distributed in macrophages and dendritic cells in the human spleen and lymph nodes.
Jiaqi Lu +5 more
doaj +4 more sources
Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer [PDF]
Frontiers in OncologyIntroductionSialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is a novel immune checkpoint, similar to programmed death-ligand (PD-L1), and has emerged as a potential target for cancer immunotherapy. Until recently, little was known about the
Chengbiao Chu +4 more
doaj +5 more sources
Immuno-PET Imaging of Siglec-15 Using the Zirconium-89-Labeled Therapeutic Antibody, NC318
Molecular Imaging, 2023 Objective. Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is overexpressed in various cancers which has led to the development of therapeutic anti-Siglec-15 monoconal antibodies (mAbs).
Elaine M. Jagoda +12 more
doaj +3 more sources
Comprehensive Analysis of SIGLEC-15 and PD-L1 Expression Identifies Distinct Prognostic Profiles in Gastric Cancer. [PDF]
Int J Mol SciGastric cancer remains a major global health burden, with limited response rates to current immunotherapies targeting the programmed death-ligand 1 (PD-1/PD-L1) axis.
Cozac-Szőke AR +13 more
europepmc +3 more sources
Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec‐15 axis in immune escape [PDF]
Cancer CommunicationsBackground Metabolic reprograming and immune escape are two hallmarks of cancer. However, how metabolic disorders drive immune escape in head and neck squamous cell carcinoma (HNSCC) remains unclear.
Xin‐Yu Zhang +7 more
doaj +3 more sources
Killing two birds with one stone: Siglec-15 targeting integrated bioactive glasses hydrogel for treatment of breast cancer bone metastasis [PDF]
Materials Today BioBone metastasis is a fatal consequence of breast cancer that occurs when patients fail to respond to conventional therapies and mainly result from a vicious cycle involving dysregulated bone homeostasis and uncontrolled tumor growth.
Chengkuan Liu +6 more
doaj +3 more sources
Siglec-15 Promotes Tumor Progression in Osteosarcoma via DUSP1/MAPK Pathway [PDF]
Frontiers in Oncology, 2021 Recurrence and metastasis are important features of osteosarcoma (OS) that cause its poor prognosis. Aberrant expression of Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) has been reported in various kinds of cancers.
Meng-ke Fan +8 more
doaj +3 more sources
Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone [PDF]
Current Oncology, 2022 The main features of a giant cell tumor of bone (GCTB) are frequent recurrence and aggressive osteolysis, which leads to a poor prognosis in patients.
Mengke Fan +5 more
doaj +3 more sources